Privately held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease.
U.K.-based Exscientia signed a three-year artificial intelligence (AI)-based drug discovery collaboration with Celgene.
As Scott Gottlieb prepares to step down from his role as commissioner of the U.S. Food and Drug Administration, he sat down with Politico to talk about his two years at the helm of the regulatory agency and what regrets he may be leaving behind.
Merck KGaA of Darmstadt, Germany and Pfizer Inc. discontinued a Phase III ovarian cancer drug trial after determining that the degree of benefit observed in the treatment during an interim analysis does not support the continuation of the study.
A market research report by Clarivate Analytics named “Cortellis Drugs to Watch” identified seven new drugs the company believes will hit sales of $1 billion or more – the so-called “blockbuster” mark – by 2023.
Sage Therapeutics shares were up after the company won approval for the postpartum depression treatment Zulresso (brexanalone).
Urovant Sciences announced positive top-line results from the company’s Phase III EMPOWUR trial of vibregron in patients with overactive bladder.
One of the groups of shareholders opposing the Bristol-Myers Squibb acquisition of Celgene is ready for a fight at the April 12, 2019, shareholder meeting.
March is National Women’s Month, and BioSpace recognized these 10 women as being especially influential in the biopharma industry.